Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

16 Dec 2012

Abstract excerpt

Immune targeting of B-cell malignancies using chimeric antigen receptors (CARs) is a promising new approach, but critical factors impacting CAR efficacy remain unclear. To test the suitability of targeting CD22 on precursor B-cell acute lymphoblastic leukemia (BCP-ALL), lymphoblasts from 111 patients with BCP-ALL were assayed for CD22 expression and all were found to be CD22-positive, with median CD22 expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23243285
DOI: 10.1182/blood-2012-06-438002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaPMID 23243285Read ↗

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARSemantic proximity Read ↗

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22Semantic proximity Read ↗

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALLSemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

Unraveling Cellular and Molecular Mechanisms of Relapse in CD19/CD22 Dual-Targeting CAR T Therapy for B-ALLSemantic proximity Read ↗

CARPOOL: A library-based platform to rapidly identify next generation chimeric antigen receptorsSemantic proximity Read ↗

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity Read ↗

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read ↗

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read ↗

CAR-T Cell TherapySemantic proximity Read ↗

Humanized CAR T cells targeting p95HER2Semantic proximity Read ↗

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.